Healthcare Industry News: Cytogen
News Release - January 14, 2008
Joseph A. Mollica Named Chairman of Celator(R) Pharmaceuticals Board of DirectorsPRINCETON, N.J., Jan. 14 (HSMN NewsFeed) -- Celator Pharmaceuticals, a biotechnology company working to develop improved combination chemotherapy, announced today that Joseph A. Mollica, Ph.D., chairman of Pharmacopeia Drug Discovery Inc., has been named chairman of the Celator board of directors.
Dr. Mollica joined Pharmacopeia in 1994 where he served as president and chief executive officer prior to being named chairman in 2004. Before joining Pharmacopeia, Dr. Mollica was employed by the DuPont Company and then by the DuPont Merck Pharmaceutical Company where, from 1991-1993, he served as president and chief executive officer and previously as vice president, Medical Products at DuPont. Dr. Mollica was also employed at Ciba-Geigy from 1966-1986 rising to senior vice president of the pharmaceutical division during his tenure. Currently, Dr. Mollica is also on the boards of Redpoint Bio, Cytogen, and Neurocrine Biosciences.
"Dr. Mollica's extensive experience in drug discovery and business development will be a vital asset to Celator as we plan for our continued growth in the years ahead," said Dr. Andrew Janoff, CEO of Celator Pharmaceuticals. "We enthusiastically welcome Dr. Mollica to our team and are looking forward to working with him as we advance our promising pipeline of combination chemotherapies to commercialization."
Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit www.clinicaltrials.gov and search "Celator"); CPX 571, now positioned to advance to Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.
Source: Celator Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.